Correlation Between Histogen and Galera Therapeutics
Can any of the company-specific risk be diversified away by investing in both Histogen and Galera Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Histogen and Galera Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Histogen and Galera Therapeutics, you can compare the effects of market volatilities on Histogen and Galera Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Histogen with a short position of Galera Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Histogen and Galera Therapeutics.
Diversification Opportunities for Histogen and Galera Therapeutics
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Histogen and Galera is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Histogen and Galera Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Galera Therapeutics and Histogen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Histogen are associated (or correlated) with Galera Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Galera Therapeutics has no effect on the direction of Histogen i.e., Histogen and Galera Therapeutics go up and down completely randomly.
Pair Corralation between Histogen and Galera Therapeutics
If you would invest 36.00 in Histogen on November 9, 2024 and sell it today you would lose (33.30) from holding Histogen or give up 92.5% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Flat |
| Strength | Insignificant |
| Accuracy | 0.0% |
| Values | Daily Returns |
Histogen vs. Galera Therapeutics
Performance |
| Timeline |
| Histogen |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
| Galera Therapeutics |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Histogen and Galera Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Histogen and Galera Therapeutics
The main advantage of trading using opposite Histogen and Galera Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Histogen position performs unexpectedly, Galera Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galera Therapeutics will offset losses from the drop in Galera Therapeutics' long position.| Histogen vs. Virax Biolabs Group | Histogen vs. Artelo Biosciences | Histogen vs. Curis Inc | Histogen vs. SAB Biotherapeutics |
| Galera Therapeutics vs. Mereo BioPharma Group | Galera Therapeutics vs. Terns Pharmaceuticals | Galera Therapeutics vs. PDS Biotechnology Corp | Galera Therapeutics vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Complementary Tools
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |